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Background: Interleukin 6 (IL-6)-mediated signal transducers and activators of transcription 3 (STAT-3)
phosphorylation (activation) is aberrantly sustained in cholangiocarcinoma cells resulting in enhanced myeloid cell
leukemia 1 (Mcl-1) expression and resistance to apoptosis. FTY720, a new immunosuppressant, derived from ISP-1,
has been studied for its putative anti-cancer properties. This study aimed to elucidate the mechanism by which
FTY720 mediates antitumor effects in cholangiocarcinoma (CC) cells.
Methods: Three CC cell lines were examined, QBC939, TFK-1, and HuCCT1. The therapeutic effects of FTY720 were
evaluated in vitro and in vivo. Cell proliferation, apoptosis, cell cycle, invasive potential, and epithelial- mesenchy-mal
transition (EMT) were examined.
Results: FTY720 greatly inhibited CC cells proliferation and EMT in vitro and in vivo, and this effect was associated
with dephosphorylation of STAT3tyr705. FTY720 induced apoptosis and G1 phase arrest in CC cells, and inhibited
invasion of CC cells. Western blot analysis showed that FTY720 induced cleavage of caspases 3, 8 and 9, and of
PARP, in a dose-dependent manner, consistent with a substantial decrease in p-STAT3, Bcl-xL, Bcl-2, survivin, cyclin
D1, cyclin E, N-cadherin, vimentin, VEGF and TWIST1. In vivo studies showed that tumor growth and metastasis were
significantly suppressed after FTY720 treatment.
Conclusions: These results suggest that FTY720 induces a significant decrease in p-STAT3, which inhibits
proliferation and EMT of CC cells, and then induces G1 phase arrest and apoptosis. We have characterized a novel
immunosuppressant, which shows potential anti-tumor effects on CC via p-STAT3 inhibition. FTY720 merits
further investigation and warrants clinical evaluation.
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Human cholangiocarcinoma (CC) arises from the epithe-
lium of the biliary tree. CC encompasses adenocarcin-
omas arising in the intra or extrahepatic biliary tree and
in the gall bladder. CC is a relatively uncommon malig-
nancy in western countries [1], but has a high incidence* Correspondence: liulianxin@ems.hrbmu.edu.cn
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unless otherwise stated.in Asia and Latin America [2,3]. CC is characterized by
poor prognosis and a 5-year survival rate less than 5%
[4]. Currently, conventional chemotherapy and radiother-
apy have not been reported to be effective in improving
long-term survival [5], the only curative treatment for CC
is surgical resection. However, the majority of CC patients
shows advanced liver involvement and metastasis, and this
precludes the use of curative surgical resection. Therefore,
there is an urgent need to define the molecular mecha-
nisms underlying CC proliferation and metastasis in order
to develop novel therapeutic strategies.
One promising candidate for CC targeted therapy is
signal transducer and activator of transcription 3 (STAT3).This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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activated in many types of cancer, contributing to tumor
progression via several mechanisms. [6-9] When phos-
phorylated at tyrosine705, STAT3 undergoes translocation
from the cytosol to the nucleus, where it functions as a
pivotal transcription factor upregulating gene transcrip-
tion [10-12]. IL-6 secretion can further increase STAT3
activation levels within tumor cells via an autocrine feed-
back loop [6]. IL-6–activated STAT3 is crucial for survival
of several types of cancer cell, including multiple mye-
loma, a plasmacytic B-cell malignancy [6,13]. Studies sug-
gest that IL-6/STAT3 signaling is aberrant in human
CC cells and CC tissues with prolonged and sustained
STAT-3 phosphorylation [14,15]. The mechanisms re-
sponsible for this atypical IL-6 signaling response are
unclear but of pathophysiological importance.
FTY720 is a synthetic sphingosine immunosuppres-
sant, which is currently undergoing clinical trials for the
prevention of kidney graft rejection [16] and the treat-
ment of relapsing multiple sclerosis [17]. Previous studies
indicate that the effect of FTY720 on prolonging the sur-
vival of allografts is attributable to the ability of its phos-
phorylated metabolite to inhibit T-lymphocyte infiltration
by targeting several of the sphingosine-1-phosphate (S1P)
receptors [18,19]. Recently, FTY720 has been reported to
have a strong antitumor effect on breast cancer [20], blad-
der cancer [21] and leukemia [22]. So far, the feasibility of
using this drug in CC treatment has not been studied. The
precise mechanism of FTY720 action on cancer cells is
not completely understood. Therefore, in this study we
aimed to investigate the in vitro and in vivo anticancer po-
tential of FTY720 and to ascertain the precise mechanism
by which proliferation and metastasis are inhibited in
CC cells.
We investigated the effect of FTY720 on the STAT3
cell survival pathway and found that STAT3 dephosphory-
lation plays a central role in cell growth arrest, apoptosis
and metastasis upon administration of FTY720 to CC cell
lines. Dephosphorylation of STAT3tyr705 results in G1 ar-
rest and apoptosis possibly by up-regulation of p27, cleav-
age of caspase-3 and down-regulation of Mcl-1, cyclin D1
and Bcl-xL. It might also inhibit EMT by up-regulation
of E-cadherin and down-regulation of Vimentin and
N-cadherin, both in vitro and in vivo.
Methods
Cell lines and reagents
The human CC cell line QBC939 was a gift from Prof.
Shuguang Wang (Third Military Medical University,
Chongqing, China). Human CC cell lines TFK-1 and
HuCCT1 were kindly provided by the Cancer Cell Reposi-
tory, Tohoku University, Japan. All cell lines were cultured
in Dulbecco’s modified Eagle's medium (DMEM; Gibco
BRL, Grand Island, NY, USA) supplemented with 10%fetal bovine serum (Gibco BRL), penicillin G (100,000 U/L)
and streptomycin (100 mg/L; Gibco BRL) at 37°C in a hu-
midified atmosphere containing 5% CO2. FTY720 was pur-
chased from Selleckchem (Houston, TX, USA).
MTT assay
Cell viability was assessed using the MTT assay. CC cells
were seeded at 2 × 104 per well in 96-well flat-bottomed
plates and incubated in 10% FBS supplemented DMEM
for 24 h. Cells were treated with FTY720 at various con-
centrations in the same medium. Controls received di-
methyl sulfoxide (DMSO) vehicle at a concentration equal
to that in drug-treated cells. After 24 and 48 h, the drug-
containing medium was replaced with 200 μL of 10% FBS
supplemented DMEM containing 0.5 mg/mL MTT, and
cells were incubated in the CO2 incubator at 37°C for 4 h.
Medium was removed and the reduced MTT solubilized
in 100 μL per well of DMSO. Absorbance was then mea-
sured at 570 nm. Six replicates were performed for each
experiment.
Cell cycle analysis
Cells were treated with FTY720 and then 106 cells were
fixed in 80% ethanol at -20°C for 24 h. Fixed cells were
stained according to the Cycle TESTTM PLUS DNA Re-
agent Kit protocol (BD Biosciences, San Jose, CA, USA)
and analyzed by flow cytometry (Beckman Coulter FC
500). The experiment was repeated thrice under the same
conditions.
Apoptosis analysis
FTY720 treated cells were harvested, washed twice with
prechilled PBS and resuspended in 1× binding buffer at
a concentration of 1 × 106 cells/ml. One hundred micro-
liters of this cell suspension (1 × 105 cells) was mixed
with 5 μl of Annexin V-FITC and 5 μl of propidium iodide
(PI) (BD Biosciences) according to the manufacturer’s in-
structions. The mixed solution was gently vortexed and
incubated in the dark at room temperature (25°C) for
15 min. Four hundred microliters of 1× dilution buffer
were then added to each tube and cell apoptosis analysis
was performed by flow cytometry (BD FACS Calibur)
within 1 h.
Cell invasion assays
Eight hours after FTY720 treatment, invasion was mea-
sured using 24-well BioCoat cell culture inserts (BD
Biosciences, NJ, USA) with an 8 μm porosity polyethylene
terephthalate membrane coated with Matrigel Basement
Membrane Matrix.
Tumor xenografts in nude mice
In these studies, tumor xenografts were established by
standard techniques in 8-week-old nude mice (BALBc
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neously with 3 × 106 QBC939 cells and 3 × 106 HuCCT1
cells suspended in PBS. Tumor size was measured by
Vernier calipers, and tumor volume was calculated as
described previously [24]. Once the tumors reached an
average of 90 mm3, the treatment began. For the treat-
ment group, FTY720 was administered by daily i.p. injec-
tion of 10 mg/kg/day for 20 days. After treatment, mice in
both the treatment and control groups (n = 10 in each
group) were sacrificed. Tumor tissues were collected,
snap-frozen and embedded in paraffin for further analysis.
Ethics statement
This study does not involve human subjects, human ma-
terial, or human data. All nude mice were treated and all
procedures were conducted in accordance with the guide-
lines for experimental animals approved by the Animal
Care and Use Committee of Harbin Medical University,
Harbin, China.
In vivo invasive assay
HuCCT1 cells (3 × 106 cells in 200 μL) and QBC939
(3 × 106 cells in 200 μL) were injected into the intraperito-
neal cavity as previously described [25]. Animals were ran-
domized to receive either FTY720 (10 mg/kg/d, i.p.) or
vehicle at 1 week after injection. The mice were sacrificed
at 4 weeks after tumor cell injection.
Western blot analysis
Protein isolation was performed as described previously
[26], and western blot analysis was achieved via establishedFigure 1 FTY720 is cytotoxic to CC cells in a dose- and time-dependent
with 0, 5, 10, 15 and 20 μmol/L of FTY720 for 24 h. Data are presented as mea
with FTY720 or vehicle for 72 hr, and proliferation measured using MTT assays
exposure to FTY720 (0 or 10 μmol/L) for 24 h. An increase in apoptotic cells fo
mean ± SD from three independent experiments. (D) A representative exampleprotocols [27]. The primary antibodies used were against
N-cadherin, E-cadherin, p16 and vimentin (Abcam,
Cambridge, MA, USA); p27, STST3, p-STAT3, cleaved
PARP, cleaved caspase-3, cleaved caspase-8, cleaved
caspase-9, Bcl-xL, and Bcl-2 (Cell Signaling Technology,
Danvers, MA, USA); cyclin D1, VEGF, TWIST1, Bax,
survivin, cyclin E, CDK2, CDK4 and β-actin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA).
Immunofluorescence
Briefly, cells seeded on coverslips were fixed with 4% (w/v)
paraformaldehyde (Sigma-Aldrich) for 10 min and perme-
abilized with 0.1% (v/v) Triton X-100 for 5 min at room
temperature. The cells were then incubated overnight
with primary antibodies at 4°C, followed by incubation
with fluorescent secondary antibody for 1 h at room
temperature. After final washes with PBS, coverslips were
mounted using an anti-fade mounting solution containing
4',6-diamidino-2-phenylindole (DAPI; Vector Lab) and
images were examined and captured.
Immunohistochemistry
Immunohistochemistry was performed as described pre-
viously [28] using Ki-67, CD31 and cleaved caspase-3
antibodies (Cell Signaling Technology).
Statistical analysis
All data are expressed as mean values ± standard deviation
(SD). Comparisons among multiple groups were made
with a one-way analysis of variance followed by Dunnett'smanner. (A) MTT assay showing percentage of viable CC cells treated
n ± SD from three independent experiments. (B) CC cells were treated
. (C) Flow cytometry results of annexin V-PI stained CC cells after
llowing treatment with FTY720 is shown. Data are presented as the
of apoptosis of QBC939 cells treated with 10 μmol/L of FTY720 for 24 h.
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cally significant.
Results
FTY720 is a potent anti-CC agent and induces apoptosis
in CC cells
The in vitro activity of FTY720 against CC cells was
evaluated after 24 h of exposure to drug. Cells were grownFigure 2 FTY720 induces cell death in a caspase-dependent manner.
FTY720. Lysates from CC cells treated with 0, 5 and 10 μmol/L FTY720 for 2
caspase-9 and cleaved-PARP by western blotting. (B) Caspase inhibition pro
0.1% DMSO, 5 μmol/L FTY720 or a combination of Q-VD-OPH (20 μmol/L) a
are presented as the mean ± SD from three independent experiments. (C) Ly
PARP by western blotting. The western blot is representative of three indepenin the absence or presence of different concentrations
(0, 5, 10, 15 and 20 μmol/L) of FTY720, and cytotox-
icity was measured by the MTT assay. FTY720 effectively
induced cell death in all cell lines tested (Figure 1A). The
IC50 of FTY720 after 24 h of exposure to the drug was
9.81, 11.66 and 8.84 μmol/L for QBC939, TFK-1 and
HuCCT1 cells, respectively. Extending drug exposure to
72 h resulted in additional cytotoxicity, indicating that(A) Caspase activation and PARP cleavage following treatment with
4 h were probed for cleaved-caspase-3, cleaved-caspase-8, cleaved-
tects against FTY720-induced cell death. CC cells were incubated in
nd 5 μmol/L FTY720, followed by annexin V-PI staining 24 h later. Data
sates from treated cells were probed for cleaved-caspase-3 or cleaved-
dent experiments. β-Actin was used as the internal control.
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ner (Figure 1B).
To determine whether CC cell death induced by
FTY720 involves apoptosis, flow cytometric analysis
with annexin V–PI staining was performed. FTY720 in-
duced obvious apoptosis in all cell lines tested at the
dose of 10 μmol/L after 24 h (Figure 1C). Figure 1D is a
representative example of apoptosis of QBC939 cells
treated with 10 μmol/L FTY720 for 24 h.
FTY720 induces cell death in a caspase-dependent
manner by cleavage of caspases 3, 8 and 9
Next, we explored the effect of FTY720 on caspase-
dependent apoptotic pathways. FTY720 induced cleavage
of caspases 3, 8 and 9, and of PARP, in a dose-dependent
manner after 24 h incubation with the drug (Figure 2A).
To determine the dependence of FTY720-induced apop-
tosis on the caspase pathway, we assessed the ability of
the pan-caspase inhibitor, Q-VD-OPH to protect against
cell death. As shown in Figure 2B, Q-VD-OPH reduced
FTY720-induced cell death as determined by annexin
V-PI staining and the effect was only partial. We next
examined whether Q-VD-OPH actually inhibited FTY720
activation of caspase-3 as measured by processing of the
proform and downstream cleavage of PARP, which is char-
acteristic of caspase-dependent apoptosis. CC cells wereFigure 3 FTY720 reduces constitutive and inducible p-STAT3 in CC ce
proteins. (A) CC cells were treated for 24 h with or without FTY720 and an
reduced IL-6 induced p-STAT3 expression in CC cells as shown in the west
performed in triplicate.exposed to FTY720 in the presence or absence of Q-VD-
OPH and cell lysates made. As shown in Figure 2C,
Q-VD-OPH greatly diminished PARP and caspase-3
cleavage as well as preventing cell death. Together, these
data demonstrate that while apoptosis is induced by
FTY720 mainly through caspase-dependent mechanisms,
non-caspase dependent pathways may also operate.
FTY720 inhibits constitutive and inducible STAT3
phosphorylation in CC cells, and affects the expression of
anti- or proapoptotic proteins
We first evaluated the effect of FTY720 on the ex-
pression of p-STAT3 in CC cells. Figure 3A shows that
treatment of CC cells with FTY720 for 24 h significantly
reduced the level of in tyrosine-phosphorylated STAT3
although total STAT3 was unaffected. FTY720 treatment
also strongly decreased the expression of Bcl-xL, Bcl-2,
survivin and increased the expression of Bax in CC cells.
Next, we examined whether FTY720 could inhibit IL-6-
induced STAT3 phosphorylation in CC cells. CC cells
were pretreated with FTY720 (5 μM) for 24 h and then
stimulated with IL-6 (10 ng/ml) for 15 min. As shown in
Figure 3B, IL-6 induced STAT3 phosphorylation was re-
duced by FTY720. These results indicate that the STAT3
pathway is likely to be an important target of FTY720 in
CC cells.lls, and downregulates the expression of anti- or proapoptotic
alyzed for the indicated protein by western blotting. (B) FTY720
ern blot. β-Actin was used as the internal control. All assays were
Figure 4 Effect of FTY720 on cell cycle proteins and cell cycle progression. (A) FTY720 induces expression of p16 and p27 and reduces
expression of cyclin D1, CDK4, cyclin E and CDK2. CC cells were treated with FTY720 at the indicated concentrations for 24 h. Lysates were then
prepared immediately and analyzed by western blotting for cyclin D1, CDK4, cyclin E, CDK2, p16 and p27. β-Actin was used as the internal control.
All assays were done in triplicate. (B) Cell cycle analysis of FTY720-treated CC cells showing arrest in G1 phase. CC cells were incubated with
FTY720 for 24 h. The percentage of cells in each phase of the cell cycle is presented as the mean ± SD from three independent experiments.
Following treatment with FTY720 for 24 h, there was a significant increase in the percentage of cells in G0/G1 relative to the control group.
(C) A representative example of cell cycle arrest in QBC939 cells treated with FTY720 for 24 h.
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p27 and p16 expression and induces G1 cell cycle arrest
in CC cells
Next, we investigated the effect of FTY720 on cell cycle
arrest of CC cells. As shown in Figure 4A, reductions in
the levels of cyclin D1, CDK4, cyclin E and CDK2 were
observed after FTY720 treatment for 24 h. As increased
expression of p27 results in inhibition of proliferation,
we examined the effect of FTY720 on its expression and
on that of p16, another cell cycle inhibitor that has been
shown to be transcriptionally silenced in CC [29]. Ex-
pression of both p27 and p16 proteins was induced by
FTY720 after treatment for 24 h (Figure 4A). Consist-
ent with the above findings, cell cycle analysis showed
that FTY720 induces G1 cell cycle arrest in CC cells
(Figure 4B, C).
FTY720 inhibits the invasive potential of CC cells in vitro
To determine the function of FTY720, we treated QBC939,
TFK-1 and HuCCT1 cells with FTY720. FTY720 signifi-
cantly inhibited their invasive capacity, as compared with
DMSO-treated cells (Figure 5A). Given that FTY720 in-
hibits CC invasion, we investigated the effect of FTY720
on epithelial-mesenchymal transition (EMT), a critical
event in tumor invasion. Western blot analysis indicated a
higher expression of E-cadherin in CC cells treated withFigure 5 FTY720 inhibits the invasive potential of CC cells in vitro. (A)
and HuCCT1 cells. ***P <0.0001. The results are presented as the mean ± SD
FTY720 increased the expression of E-cadherin and decreased the expressio
used as the internal control. All assays were performed in triplicate. (C) Single
(green) and vimentin (red). The cell nucleus is stained blue by DAPI.FTY720. In contrast, the expression of N-cadherin, vimen-
tin, VEGF and TWIST1 decreased in FTY720 treated CC
cells (Figure 5B). As shown by immunofluorescence
(Figure 5C), FTY720 markedly reduced N-cadherin and
vimentin levels in CC cells, which was in good agreement
with the results in Figure 5B.
FTY720 inhibits tumor growth and metastasis of CC in vivo
We further examined the effect of FTY720 on CC
growth by establishing a xenograft CC model in nude
mice. QBC939 and HuCCT1 was used for in vivo stu-
dies. Compared with the control group, FTY720 treat-
ment resulted in a significant decrease of tumor size
(Figure 6A and Additional file 1: Figure S1). The effects
of FTY720 on the metastatic phenotype of CC were also
examined in vivo by implanting HuCCT1 and QBC939
cells into the peritoneal cavity of nude mice. Necropsy
after 4 weeks revealed that the control cells extensively
colonized the visceral organs and formed multiple meta-
static nodules (Figure 6B and Additional file 2: Figure S2),
while the number of metastatic nodules was reduced in
FTY720-treated mice. In addition, the body weight of
mice from treated group was similar to the control
group (Additional file 3: Figure S3A and S3B), indicating
FTY720 suppress CC growth and metastasis without
notable toxic side-effects. Immunohistochemistry showedFTY720 significantly inhibited the invasive capacity of QBC939, TFK-1
of experiments performed in triplicate. (B) Western blot showing that
n of N-cadherin, vimentin, VEGF and TWIST1 in CC cells. β-Actin was
and merged images show immunofluorescence staining of N-cadherin
Figure 6 FTY720 inhibits proliferation and metastasis of CC in vivo. (A) Photomicrographs of xenograft tumors in nude mice. Representative
images of a mouse in each group are presented. Tumor volumes in FTY720-treated mice were smaller than those of control mice. (B) The
multiple tumor masses formed by the HuCCT1 cells in the FTY720-treated group were much smaller than those formed by HuCCT1 cells in the
control group. (C) Tumors from different groups were immunostained for indicated molecules. CD31-stained microvessels were counted to record
microvessel density. Apoptotic cells were counted to give the apoptosis index and cells expressing Ki-67 were counted to calculate the proliferation
index. Pictures are representative of three independent experiments. (D) Western blot detection of the indicated molecules in tumor samples. β-Actin
was used as the internal control. All assays were performed in triplicate. The results are expressed as the mean ± SD of three independent experiments;
***P <0.0001.
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ferent groups (Figure 6C) respectively assess tumors’ abil-
ity of proliferation, apoptosis, and forming microvessels.
The relative levels of the above mentioned proteins were
also analyzed in the different groups by western blotting
(Figure 6D). Together, these results reveal a high propen-
sity of FTY720 to inhibit proliferation and metastasis
in CC.
Discussion
Cholangiocarcinoma is an aggressive disease, with a poor
response to the treatments that are currently available,
including the standard gemcitabine [30,31]. To this end,we examined a new agent for the treatment of CC.
FTY720 is a chemical substance derived by modifying an
immunosuppressive metabolite and has been shown to
possess anti-cancer properties in various types of cancer
[32]. However, the efficacy of FTY720 against CC has
not been previously assessed. Herein, we have demon-
strated that FTY720 induces apoptosis and cell cycle
arrest, inhibits EMT of CC cells and in vivo tumor
growth in a nude mouse model without notable toxic
side-effects.
The IL-6/STAT3 pathway plays an important role in hu-
man cancers. STAT proteins comprise a seven member
family of latent cytoplasmic transcription factors [10,33].
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and in particular STAT3 initiated cascades, participate
in the development and progression of human cancers
[10,11]. Numerous studies have shown that STAT3 inhibi-
tors have tumor suppressive effects on various tumors.
AG490, the most popular STAT3 inhibitor, can induce CC
cell apoptosis and inhibit CC/mycosis fungoides tumor
cell proliferation [14,15,34]. New STAT3 inhibitors also
can inhibit tumor proliferation [35,36], chemo-therapy re-
sistance [37] and metastasis [38]. We therefore presumed
that STAT3 would be a good target for CC treatment, and
our results indeed show that FTY720 inhibited prolife-
ration and EMT in CC mainly through the IL-6/STAT3
pathway.
FTY720 has been demonstrated to inhibit proliferation
of various tumors [20,39,40]. So we tried to test whether
FTY720 could inhibit CC proliferation. Cell viability ana-
lysis (MTT assays) showed that FTY720 could induce a
dramatic reduction in cell viability in all three CC cell
lines tested. After cells were treated with FTY720 for 24 h,
we observed a significant decrease in the S-phase popu-
lation, and induction of G1 arrest. FTY720 induced sig-
nificant expression of the cyclin-dependent kinase (CDK)
inhibitors p16 and p27. Both p16 and p27 block the for-
mation of cyclin-CDK complexes, allowing Rb to become
activated and to halt the cell cycle. In addition to inducing
p16 and p27, FTY720 also downregulated cyclin D1 and
cyclin E in CC cells contributing to arrest in the G1 phase.
FACS analysis also showed that the inhibitory effect
on CC cell growth by FTY720 was also related to induc-
tion of apoptosis. Our results show that FTY720-induced
apoptosis is associated with cleavage of caspases 8, 9 and
3, and PARP, suggesting that the drug activates both
the extrinsic and intrinsic apoptotic pathways. Further,
FTY720-induced apoptosis is in large part dependent
on caspase activation. In CC cells, FTY720 also mod-
ulates the expression of the antiapoptotic proteins. Of the
Bcl-2 family members, the expression of Bcl-xL, Bcl-2 and
survivin was significantly reduced, while Bax expression
was increased. In additional to inhibition of tumor prolif-
eration, numerous studies demonstrated that FTY720
could inhibit tumor metastasis [20,41,42]. And our study
also demonstrate that incubation of CC cells with FTY720
leads to the loss of N-cadherin and vimentin and to the
accumulation of E-cadherin. Furthermore, FTY720 signifi-
cantly inhibited the invasive capacity of CC cells. We also
examined the ability of FTY720 to suppress the growth
and metastasis of human CC cancer cell xenografts in
nude mice. We found a significant reduction in relative
tumor size and metastatic nodules in FTY720-treated ani-
mals compared with untreated controls. In addition, the
suppression of proliferation by FTY720 was confirmed by
decreased Ki-67 expression. Increased numbers of apop-
totic cells and activated protein levels of apoptosis–relatedproteins, such as cleaved-PARP, cleaved-caspase-9, cleaved-
caspase-8 and cleaved-caspase-3, were accompanied by
decreased p-STAT3 expression in the FTY720-treated
animals.
IL-6 plays an important role in the growth and survival
of CC cells [43,44]. Our results indicate that FTY720
exerts an important inhibitory effect on the IL-6 signal
transduction pathway by inhibiting constitutive and indu-
cible STAT3 phosphorylation. STAT3 directly and indir-
ectly upregulates the expression of genes that are required
for uncontrolled proliferation and invasion of tumor cells
[45,46]. In our study, the FTY720-induced reduction of
Bcl-xL, Bcl-2, N-cadherin, vimentin, cyclin E and cyclin
D1 may result, at least in part, through an inhibitory effect
on the STAT3 pathway. Importantly, FTY720 overcomes
the activation of p-STST3 which was induced by IL-6.
Conclusions
In conclusion, our results show that the novel synthetic
sphingosine immunosuppressant, FTY720, has potent
activity against CC in vitro and in vivo. Its ability to tar-
get mainly the IL-6/STAT3 pathway and downstream
anti-apoptotic, EMT and cell cycle proteins, suggest its
viability as part of the therapeutic armamentarium for
CC. Our results provide preclinical rationale for clinical
development of FTY720 for the treatment of CC.
Additional files
Additional file 1: Figure S1. FTY720 inhibits proliferation of CC in vivo.
Photomicrographs of xenograft tumors in nude mice. Representative
images of a mouse in each group are presented. Tumor volumes in
FTY720-treated mice were smaller than those of control mice. *P < 0.05.
Additional file 2: Figure S2. FTY720 inhibits metastasis of CC in vivo.
The multiple tumor masses formed by the QBC939 cells in the FTY720-
treated group were much smaller than those formed by QBC939 cells in
the control group. *P < 0.05.
Additional file 3: Figure S3. The graph showed the body weight of
the animals with tumor xenografts/without tumor xenografts in the
control and treatment groups throughout the treatment period.
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